TABLE 5

Unadjusted and adjusted effects of triple therapy compared with dual bronchodilation (baseline) on outcomes of interest during the outcome period

OutcomePatientsUnadjustedAdjusted
HR (95% CI)p-valueHR (95% CI)p-value
First exacerbation16470.90 (0.79–1.02)0.1110.87 (0.76–0.99)0.040
First acute respiratory event16470.79 (0.70–0.88)<0.001*0.74 (0.66–0.84)<0.001*
Treatment failure16470.86 (0.76–0.98)0.0200.83 (0.73–0.95)0.005*
First acute OCS course16470.95 (0.82–1.09)0.4370.93 (0.80–1.07)0.298
First antibiotics course16470.91 (0.79–1.04)0.1710.89 (0.77–1.04)0.138
Pneumonia diagnosis16471.26 (0.80–1.98)0.3250.71 (0.21–2.38)0.573
RR (95% CI)p-valueRR (95% CI)p-value
Exacerbation rate11380.85 (0.73–1.00)0.0560.86 (0.73–1.01)0.068
Acute OCS courses rate11380.83 (0.68–1.01)0.0670.80 (0.66–0.98)0.030
Antibiotics courses rate11380.88 (0.72–1.06)0.1830.91 (0.75–1.10)0.332
Acute respiratory events rate11380.80 (0.70–0.90)<0.0010.79 (0.70–0.90)<0.001*
OR (95% CI)p-valueRR (95% CI)p-value
mMRC ≥28851.20 (0.86–1.68)0.2931.12 (0.76–1.66)0.566

HR: hazard ratio; OCS: oral corticosteroid; mMRC: modified Medical Research Council dyspnoea scale; RR: rate ratio. *: p<0.05 after controlling for 10 statistical tests for secondary outcomes performed following Holm's method [22].